498 related articles for article (PubMed ID: 29019285)
1. PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India.
Guru SA; Mir R; Bhat M; Najar I; Zuberi M; Sumi M; Masroor M; Gupta N; Saxena A
Tumour Biol; 2017 Oct; 39(10):1010428317713857. PubMed ID: 29019285
[TBL] [Abstract][Full Text] [Related]
2. MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.
Liu YC; Hsiao HH; Yang WC; Liu TC; Chang CS; Yang MY; Lin PM; Hsu JF; Lee CP; Lin SF
Mol Carcinog; 2014 Dec; 53(12):951-9. PubMed ID: 23818300
[TBL] [Abstract][Full Text] [Related]
3. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM
Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761
[TBL] [Abstract][Full Text] [Related]
4. Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients.
Annuar AA; Ankathil R; Mohd Yunus N; Husin A; Ab Rajab NS; Abdul Aziz AA; Ibrahim MI; Sulong S
Asian Pac J Cancer Prev; 2021 Feb; 22(2):565-571. PubMed ID: 33639675
[TBL] [Abstract][Full Text] [Related]
5. A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1185-9. PubMed ID: 26546461
[TBL] [Abstract][Full Text] [Related]
6. A deletion polymorphism in the RIZ gene is associated with increased progression of imatinib treated chronic myeloid leukemia patients.
Mir R; Najar IA; Guru S; Javaid J; Yadav P; Masroor M; Zuberi M; Farooq S; Bhat M; Gupta N; Ray PC; Saxena A
Leuk Lymphoma; 2017 Jul; 58(7):1694-1701. PubMed ID: 27830966
[TBL] [Abstract][Full Text] [Related]
7. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
Bedewy AM; El-Maghraby SM
Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
[TBL] [Abstract][Full Text] [Related]
8. Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.
Salimizand H; Amini S; Abdi M; Ghaderi B; Azadi NA
Tumour Biol; 2016 Jan; 37(1):791-8. PubMed ID: 26250462
[TBL] [Abstract][Full Text] [Related]
9. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
Ben Hassine I; Gharbi H; Soltani I; Ben Hadj Othman H; Farrah A; Amouri H; Teber M; Ghedira H; Ben Youssef Y; Safra I; Abbes S; Menif S
Cancer Chemother Pharmacol; 2017 Oct; 80(4):829-839. PubMed ID: 28836054
[TBL] [Abstract][Full Text] [Related]
10. hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.
Ben Hassine I; Gharbi H; Soltani I; Teber M; Farrah A; Ben Hadj Othman H; Amouri H; Bellaaj H; Lakhal RB; Romdhane NB; Abbes S; Menif S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):737-745. PubMed ID: 28286932
[TBL] [Abstract][Full Text] [Related]
11. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients.
Elghannam DM; Ibrahim L; Ebrahim MA; Azmy E; Hakem H
Hematology; 2014 Apr; 19(3):123-8. PubMed ID: 23683876
[TBL] [Abstract][Full Text] [Related]
12. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
[TBL] [Abstract][Full Text] [Related]
13. [Molecular mechanism of imatinib-induced thrombocytopenia in treatment of patients with CML].
Shu LL; Jiang QL; Meng FY; Yang M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1314-8. PubMed ID: 22040995
[TBL] [Abstract][Full Text] [Related]
14. Association of Vascular Endothelial Growth Factor A (VEGFA) and its Receptor (VEGFR2) Gene Polymorphisms with Risk of Chronic Myeloid Leukemia and Influence on Clinical Outcome.
Lakkireddy S; Aula S; Kapley A; Swamy AV; Digumarti RR; Kutala VK; Jamil K
Mol Diagn Ther; 2016 Feb; 20(1):33-44. PubMed ID: 26476544
[TBL] [Abstract][Full Text] [Related]
15. C1236T polymorphism in MDR1 gene correlates with therapeutic response to imatinib mesylate in Indian patients with chronic myeloid leukaemia.
Chhikara S; Sazawal S; Mishra P; Chaubey R; Mahapatra M; Saxena R
Natl Med J India; 2015; 28(6):272-5. PubMed ID: 27294449
[TBL] [Abstract][Full Text] [Related]
16. A Genetic Variant of rs145204276 in the Promoter Region of Long Noncoding RNA GAS5 Is Associated With a Reduced Risk of Breast Cancer.
Tang Y; Wang Y; Wang X; Liu Y; Zheng K
Clin Breast Cancer; 2019 Jun; 19(3):e415-e421. PubMed ID: 30846409
[TBL] [Abstract][Full Text] [Related]
17. Impact of ABCB1 Gene Polymorphisms and Smoking on the Susceptibility Risk of Chronic Myeloid Leukemia and Cytogenetic Response.
Mohammadi F; Shafiei M; Assad D; Rostami G; Hamid M; Foroughmand AM
Iran Biomed J; 2021 Jan; 25(1):54-61. PubMed ID: 33129240
[TBL] [Abstract][Full Text] [Related]
18. OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.
Koren-Michowitz M; Buzaglo Z; Ribakovsky E; Schwarz M; Pessach I; Shimoni A; Beider K; Amariglio N; le Coutre P; Nagler A
Eur J Haematol; 2014 Apr; 92(4):283-8. PubMed ID: 24215657
[TBL] [Abstract][Full Text] [Related]
19. Novel fusion between the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with chronic myeloid leukemia-like neoplasm: undetectable residual disease after imatinib therapy.
Cluzeau T; Lippert E; Cayuela JM; Maarek O; Migeon M; Noguera ME; Dombret H; Rea D
Eur J Haematol; 2015 Nov; 95(5):480-3. PubMed ID: 25941032
[TBL] [Abstract][Full Text] [Related]
20. Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment.
Jaruskova M; Curik N; Hercog R; Polivkova V; Motlova E; Benes V; Klamova H; Pecherkova P; Belohlavkova P; Vrbacky F; Machova Polakova K
J Exp Clin Cancer Res; 2017 Apr; 36(1):55. PubMed ID: 28420426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
